CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
We sincerely hope to see you at this year’s AABB Annual Meeting in Boston, MA on October 12-16...
On September 14, 2020, our Phoenix laboratory began performing a portion of our alternate donor anti...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...
Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...
In 2016, the Procleix Panther instrument was introduced by Grifols in support of automated NAT ZIKA ...